Abiopharma

🔍 Schweiger Patrick Joseph (Executive)

Company: Oklo Inc. (OKLO)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Acquired 12,882 shares of Class A Common Stock (Direct)
  Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,991.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,561 shares of Class A Common Stock at $56.48 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,430.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 12,882 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 59,034.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 24, 2026, 12,882 RSUs were released to the Reporting Person.
• F2: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs listed in Table II. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: On March 15, 2025, the Reporting Person was granted 38,648 RSUs, vesting as to one-third of the underlying shares on March 15, 2026 and thereafter in substantially equal monthly installments.